3 RD PRESENTATION. POTENTIAL PROBLEMS Dosing (restlessness, vomiting) Drug resistance by cancer cells.

Slides:

Advertisements

Similar presentations

Single-Patient Use of Investigational Drugs and Biologic Products for Treating Cancer Grant Williams, M.D. Medical Team Leader DODP/CDER/FDA.

Advertisements

Vitamin D3 for Health, Cancer Prevention and Recovery Georgia Tetlow, MD.

EXPERIMENTAL DESIGN EXTRACTION OF LIMONENE FROM ORANGE PEELS

‍‍‍‍Chemotherapy in epithelial ovarian cancer. Dr.Azarm.

 Define and describe nanotechnology in cancer treatment  List and describe nanotechnology in cancer treatment hardware and software  Identify, describe.

VACM-1! By Michael Hledin and Gabe Marquez. Introduction VACM-1 stands for Vasopressin-Activated Calcium Mobilizing Receptor AKA Cullin5 It encodes a.

Title, in bold style Subtitle, in regular Max 3 lines of text totally NB! The graphic outside the slide will not show in “Slide Show” or on print WntResearch.

The Power of Fruits & Vegetables Fruits and Veggies Increase Visual Function and May prevent Eye Diseases, Journal of Food Science 2009 Lutein and Zeaxanthin.

PROBLEM: TUMORS. HYPOTHESIS LIMONENE IN ORANGE PEELS PREVENTS THE GROWTH OF TUMORS IN OUR BODY.

Medical Science Dr Linda Lefievre

1 The Chemoprevention of Sporadic Colorectal Cancer Issues Surrounding a Benefit/Risk Analysis in Clinical Trials Mark Avigan MD CM Medical Officer Division.

PROPOLIS and CANCER An Alternative and Supplemental Therapy CMAC 2009 Glenn Perry.

New York University Department of Radiation Oncology A Phase I-II Study of Adjuvant Concurrent Carboplatin and Accelerated Radiotherapy for Triple Negative.

Elsevier Inc. items and derived items © 2010 by Saunders, an imprint of Elsevier Inc. Chapter 100 Basic Principles of Cancer Chemotherapy.

Female Cancer Fatima Reyadh Mrs. Timm 12A March 10, 2013.

Exercise and Cancer Prepared by Joelle Lappala for CBI 360° Health.

Efficacy and Safety of Single Agent Sunitinib in Treating Advanced Hepatocelluar Carcinoma Patients After Sorafenib Failure: A Prospective, Open-Label,

Cancer 101: A Cancer Education and Training Program for [Target Population] Date Location Presented by: Presenter 1 Presenter 2.

Low dose chemotherapy with insulin (Insulin Potentiation Therapy) in combination with hormone therapy for treatment of castration resistant prostate cancer.

Timeliness of Cancer Registry Reporting Ali Johnson, CTR Vermont Cancer Registry Vermont Explor Annual Data Meeting May 1, 2006.

 Small cell lung cancer is named based on the size of the cells that cause the cancer. It accounts for about 20% of lung cancer cases.  It also referred.

Vida! Educational Series – Promoting Good Health Welcome! - We will begin shortly If viewing by internet: for technical help: Please complete.

Breast Cancer Rachel Hoenigman,Lauren Spape, and Carolyn Voorhees.

Power of science implemented in life quality Improvement of the effectiveness of radiation therapy with radiomodification by Polyplatillen and Fluoropyrimidine.

University of Texas, Southwestern Medical Center, Dallas TX

Anti-angiogenic thalidomide analogs: A determination of their teratogenic potential using a chicken egg embryo model Michelle Abramowski York College of.

Dapivirine Ring Previous Safety Experience MTN 020 Training.

Gene Therapy Clinical Trials. Cancer Gene Therapy Three Basic Approaches. Genetically alter a person's immune cells that are already naturally targeted.

. Background Paclitaxel and Irinotecan in Platinum Refractory or Resistant Small Cell Lung Cancer: a Galician Lung Cancer.

Photodynamic Therapy Lamar Institute of Technology Presented by: Amber Burks Dental Hygiene Student Danielle Chelette Dental Hygiene Student.

TAXOL® (paclitaxel) for Adjuvant Treatment of Node Positive Breast Cancer Oncologic Drugs Advisory Committee TAXOL® (paclitaxel) for Adjuvant Treatment.

 Gy  Decreased fibrosis  Enhanced local control  Deep seeded tumors isch&source=hp&biw=1366&bih=624&q=radia.

Breast Cancer By Taylor Miller. Who should care? Why? Who? Every woman Why? The facts and statistics.

In the Name of God Almighty. Investigations of IMOD TM in Management of HIV / AIDS.

1 Risk Benefit and Conclusions George Sledge, MD Indiana University School of Medicine.

CON - 1 Conclusions C David R. Parkinson Vice President, Global Head, Clinical Research and Development Novartis Pharmaceuticals Corporation.

Responses to Subsequent Anti-HER2 Therapy After Treatment with Trastuzumab-DM1 in Women with HER2- Positive Metastatic Breast Cancer 1 A Phase Ib/II Trial.

How Ashwagandha Acts Very Effectively To Reduce Stress.

Nonclinical Perspective on Initiating Phase 1 Studies for Biological Oncology Products – Case Studies Anne M. Pilaro, Ph.D. DBOP/OODP/CDER Oncology Drugs.

PHASE II TRIAL OF HYPOFRACTIONATED BREAST IRRADIATION WITH VMAT-SIB TECHNIQUE: TOXICITY AND EARLY CLINICAL ASSESSMENT IN 270 PATIENTS F. De Rose¹, F. Alongi¹,

Hypothermia for Preventing Chemotherapy-Induced Peripheral Neuropathy

Common Health Problem in KSA

Potential Role of D-Limonene in Breast Cancer Prevention

The Mammosphere- Use of 3D tumor models to study Breast Cancer

Rosell R et al. Proc ASCO 2011;Abstract 7503.

Figure 5. Treatment of the checkpoint inhibitor related toxicity

Melanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth

An overview of cancer Health 10.

From Bench to Clinical Applications: Money Talks

Basic Principles of Cancer Chemotherapy

سرطان الثدي Breast Cancer

PARP Inhibitors and Cancer: What Do You Need to Know?

Treatment of HR+ Breast Cancer: A Clinical Update

Inactivation of Stat3 in tumor cells

Chapter 28 Cancer.

Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.

Potential clinical actionability.

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Clinical applications of CTCs and ctDNA as liquid biopsy for personalized medicine. Clinical applications of CTCs and ctDNA as liquid biopsy for personalized.

Fig. 1. scRNA-seq applications in cancer medicine.

Lung Cancer: A Wily Genetic Opponent

Effects of Pharmacokinetic Processes and Varied Dosing Schedules on the Dynamics of Acquired Resistance to Erlotinib in EGFR-Mutant Lung Cancer Jasmine.

On the Design of Combination Cancer Therapy

Optimizing Front-Line Endocrine Therapy in Metastatic Breast Cancer

CDK4/6 Inhibitors.

This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the US, and data that were.

Journal of Thoracic Oncology

Matriptase-2 inhibited breast tumor development in vivo.

Proton Therapy for Thymic Malignancies: Multi-institutional Patterns-of-Care and Early Clinical Outcomes from the Proton Collaborative Group Registry &

A Review of First-Line Treatment for Small-cell Lung Cancer

Presentation transcript:

3 RD PRESENTATION

POTENTIAL PROBLEMS Dosing (restlessness, vomiting) Drug resistance by cancer cells

ALTERNATIVE APPROACH The maximum tolerated dose is set at 8 grams/m2 or 16 grams/day for period of four weeks in humans. Cancer cells might become resistant to limonene in future. Perillyl alcohol can be used to support limonene because it has a strong chemopreventive effect in cancer treatment and its invivo test shown no toxic effect in rats and have no toxic effect in humans. It is obtained from cherries and other fruits.

Feasibility Jessica A. Miller, Patricia A. Thompson, Iman A. Hakim, Ana Maria Lopez, Cynthia A. Thomson, Wade Chew, Sherry Chow (University of Arizona cancer research and Zuckerman college of public health) in March, was accepted in August, 2012 and Published in October,2012. They maintained a 16gram of limonene per day in four women with breast cancer for 4weeks. Result: they found out that limonene causes no toxic effect in humans and also causes huge reduction to cancer growth. They also found that limonene has great reduction effect at the early stage of cancer and tumor growth.

Conclusions: Since limonene causes no toxic effect in humans, and it can be supported with perillyl alcohol to increase its ability in cancer and tumor inhibition, I strongly proposed that limonene should be used in cancer therapy.

REFERENCES Jessica A. Miller, Patricia A. Thompson, Iman A. Hakim, Ana Maria Lopez, Cynthia A. Thomson, Wade Chew, Chiu-Hsieh Hsu, H.-H. Sherry Chow. Safety and feasibility of limonene, Journal of Cancer Therapy, 2012, 3, Young Life Research Clinic.” Lmonene and Tumor”. Young Living Research. P Sept Web 26 Sept Arizona Cancer Center. “Cancer Research” N.P. May Web.